News
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 7, 2025 /PRNewswire/ -- USA News Group News Commentary - This week in Geneva, the World Health ...
Artificial Intelligence (AI) technology co-developed by DeepMind and Moorfields Eye Hospital in London shows a potential to work alongside ophthalmologists to accelerate the diagnosis and help to ...
9h
HealthDay on MSNPrevalence, Incidence of Diabetic Retinal Disease Increased in Recent YearsThe prevalence and incidence of diabetic retinal disease (DRD) has increased in recent years, while the incidence of ...
It's a strategic and scalable approach to one of the biggest gaps in modern healthcare: detecting chronic conditions like diabetic retinopathy before symptoms appear. Avant and Ainnova are now proving ...
Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...
As artificial intelligence reshapes the future of medicine, understanding how patients actually feel about it is becoming ...
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence reshapes the future of medicine, understanding ...
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, /PRNewswire/ -- USA News Group News ...
Baystreet.ca News Commentary – As AI reshapes the future of medicine, understanding how patients actually feel about it is becoming just as critical as the tech itself. According ...
Lucent Vision Shares Insight Into Safety, Risks, and Success Rates of Cataract Surgery With Diabetes
Cataract surgery is the most commonly performed eye surgery in the ophthalmology, with a track record of improving vision and ...
Baystreet.ca News Commentary – Later this week in Geneva, Switzerland, the World Health Organization (WHO) will be hosting a workshop session titled “Enabling AI for ...
13h
Clinical Trials Arena on MSNBoehringer begins Phase II trial of BI 1815368 for diabetic macular oedemaThe study targets adults aged 18 years and above affected by a subtype known as centre-involved diabetic macular oedema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results